Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, February 2002, p. 575-577, Vol. 46, No. 2
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.46.2.575-577.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Pharmacy, College of Pharmacy, Chonnam National University, Kwangju,1 and Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Kyunggi-Do, Korea2
Received 7 September 2000/ Returned for modification 27 February 2001/ Accepted 4 November 2001
The stability of DA-1131 to renal dipeptidase (RDPase) (EC 3.4.13.19) was compared with that of imipenem and meropenem by Vmax/Km ratios as an index of the enzyme's preference for substrates. Our results showed a decreasing order of imipenem (6.24), meropenem (2.41), and DA-1131 (1.39). The biochemical evaluation of DA-1131 as the least preferred substrate of RDPase suggests its potential use as a novel ß-lactam antibiotic which may be usable without coadministration of RDPase inhibitors once its clinical suitability is proven.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»